Beyond Nerves: Non-Neuronal Targets for Next-Generation Migraine Therapy | Research

The takeaway

Migraine involves activation of meningeal immune cells, vascular smooth muscle, and endothelial cells alongside neurons, with CGRP and other peptides acting on these non-neuronal targets to drive the attack.

Beyond neurons
Migraine involves meningeal immune cells, vascular smooth muscle, and endothelium as active participants, not just nerve dysfunction

What the researchers found

Non-neuronal targets in migraine include meningeal immune cells, vascular smooth muscle, and endothelial cells, all modulated by CGRP and other neuropeptides, offering additional therapeutic opportunities beyond neuronal targeting.

Why it matters

Understanding migraine as more than a nerve disease reveals why some patients don't respond to current treatments and identifies new drug targets.

How the study worked

Narrative review of non-neuronal cellular targets in migraine pathophysiology, focusing on immune, vascular, and endothelial mechanisms and their interactions with neuropeptides.

What this study cannot tell us

Many non-neuronal mechanisms are from animal models. Human validation of specific cellular targets needed. New therapeutic approaches are mostly conceptual.

How to read the evidence

Comprehensive review integrating animal and human evidence on non-neuronal migraine mechanisms.

When this study was published

Published in 2025.

The bigger picture

Reframing migraine as a neuro-vascular-immune disorder opens entirely new therapeutic categories that could help the 40-50% of patients who don't respond to current anti-CGRP drugs.

Questions still open

Could combining anti-CGRP drugs with immune modulators improve migraine outcomes?
Which non-neuronal target is most druggable?
Do different migraine subtypes involve different non-neuronal mechanisms?

Common questions

Is migraine just a nerve problem?

No. This review shows that immune cells, blood vessels, and the cells lining blood vessels in the brain's lining all contribute to migraine attacks. CGRP and other peptides affect all these cell types, not just nerves.

Why do some people not respond to CGRP drugs?

If a patient's migraine is driven more by immune or vascular mechanisms than nerve CGRP release, blocking CGRP alone may not be sufficient. Targeting these non-neuronal components could help non-responders.

Read the original research

Non-neuronal targets for migraine therapy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, e00845

View on PubMed ↗Publisher’s paper ↗

Citation

Gliga, Otilia; Feliu-Soler, Albert; Vila-Pueyo, Marta. (2026). Non-neuronal targets for migraine therapy.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, e00845. https://doi.org/10.1016/j.neurot.2026.e00845